Introduction
With the recent medical classification of adult ADHD and potentially twice
the number of patients compared to pediatric ADHD, manufacturers are seeking new
indications in this expanding and lucrative market. Lilly's Strattera was the
first drug to exploit this, and is forecast to reach blockbuster status by 2006.
Consequently, manufacturers will need to differentiate their products from
Strattera.
Scope
- Overview of the epidemiology of adult ADHD, with an assessment of the
untapped patient potential
- Discussion of the problems facing physicians in the diagnosis of adult
ADHD
- Analysis of the current market leaders and primary contenders for market
entry, with adult ADHD-specific market forecasts
- Exploration of product positioning and life-cycle management strategies
currently used by Strattera, Adderall XR and Concerta
Report Highlights
Strattera was the first drug approved for the treatment of adult ADHD in
November 2002. Since launch Strattera has a steady sales increase from $55m in
Q1 2003 to $133m in Q4 2003, and Datamonitor has forecast Strattera to reach
blockbuster status by 2006.
Shire's Adderall XR recently received an approvable letter from the FDA for
adult ADHD and J&J's Concerta is currently in Phase III with an expected
launch in 2005. Datamonitor forecasts that both drugs will see an increase in
sales from gaining an indication for this market, although both will also
experience a decline in revenues post 2005.
Approximately 75% of adults with ADHD present with a comorbid condition, of
which anxiety and depressive disorders predominate. Datamonitor has highlighted
two drug classes, which may benefit from further investigation of the treatment
of such comorbidities in order to increase their market share in the adult ADHD
market.
Reasons to Purchase
- Analyze the commercial viability of the adult ADHD market, based on
estimated patient numbers
- Develop market entry and consolidation strategies through an understanding
of key unmet needs in the market
- Identify and assess novel R&D compounds in the adult ADHD pipeline
View Cart
